Biamino G
Arzneimittelforschung. 1977;27(9a):1814-7.
The novel diuretic (Z)-(3-methyl-4-oxo-5-piperidino-thiazolidin-2-ylidene)-acetic acid ethylester (Etozolin; Elkapin) has been investigated against a benzothiazide (Vs) and placebo on 8 volunteers. Etozolin and Vs show a dose dependent diuretic effect: 400 mg etozolin being equipotent to 75 mg Vs and 1200 mg etozolin being 2.8 times more effective than 75 mg Vs. Both substances show maximum effect 2 to 4 h after application, no differences from placebo being demonstrable 10 h after administration. There were no significant differences in potassium excretion between etozolin, Vs and placebo, etozolin and Vs causing, however, a significant excretion of sodium and chloride in contrast to placebo. Etozolin seems to act like a diuretic of the sulfonamide-type in respect to the profile of daily urinary output whereas resembling the loop-diuretic type in respect to urinary volume elimination.
新型利尿剂(Z)-(3-甲基-4-氧代-5-哌啶基-噻唑烷-2-亚基)-乙酸乙酯（依托唑啉；Elkapin）已在8名志愿者身上与一种噻嗪类利尿剂（Vs）和安慰剂进行了对比研究。依托唑啉和Vs呈现出剂量依赖性利尿作用：400毫克依托唑啉与75毫克Vs等效，1200毫克依托唑啉的效果比75毫克Vs强2.8倍。两种药物在用药后2至4小时显示出最大效果，给药10小时后与安慰剂无明显差异。依托唑啉、Vs和安慰剂之间的钾排泄无显著差异，然而，与安慰剂相比，依托唑啉和Vs会导致钠和氯的显著排泄。就每日尿量情况而言，依托唑啉的作用似乎类似于磺酰胺类利尿剂，而在尿量消除方面则类似于袢利尿剂。
